For those with T2D and HF -especially HF with reduced ejection fraction- or those who are at high risk of developing HF, chronic kidney disease, evident atherosclerotic cardiovascular disease, or any combination of these diseases, the use of SGLT-2 inhibitors with demonstrated cardiovascular benefit as an add-on metformin is recommended. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.